A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 996 participants.

Also called NCT07216482

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 996 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07216482
  • WHO UTN U1111-1319-9502
  • EU CT 2025-521495-54-00
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, Hungary, Israel, New Zealand, Spain, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07216482. Randomized; triple masking; primary purpose treatment. Start 2025-11-11 (actual); primary completion 2026-08-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Condition
Hyperlipidemia
Intervention (Drug)
Enlicitide
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Placebo for Enlicitide
Intervention (Drug)
Placebo for Rosuvastatin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct07216482
Content hash
2421b71118aa60a1d11c3d3be75368827349750c71a7e4313bc8c1a170d99a57